home > news > detailed info

Recro Gainesville Adds New Facility, Broadens Capabilities With High-Potent Processing on Deck

Gainesville, Ga., Nov. 5, 2018 (Business Wire) – Recro Gainesville has added a 24,000-square-foot facility, which includes high-potent material processing space, near its existing 97,000-square-foot contract pharmaceutical development and manufacturing plant. The company is a wholly owned subsidiary of Recro Pharma, Inc., and a leading provider of solid oral dose development and manufacturing services for the pharmaceutical industry.

The expanded capabilities will allow Recro Gainesville to provide clients with a broader range of contract development and manufacturing organization (CDMO) services, from benchtop through commercialization. Clients can obtain manufacturing services ranging from formulation and development through clinical trial material (CTM) production for Phase I and beyond.

In addition, a specialized area within the new site will be opened by the end of the year to support clients with development through commercialization for high-potency compounds, a rapidly expanding category of pharmaceuticals, which includes many immune modulation and anti-cancer agents.

“The new square footage allows for early feasibility studies, enabling clients to quickly determine the best formulation path forward at laboratory scale, and subsequent scale-up to the GMP manufacture of CTMs,” said Scott Rizzo, general manager of Recro Gainesville. “This added development capability will save our clients both time and resources.”

“Also, by adding high-potency capabilities, we are continuing to provide our clients with the most comprehensive, highest-quality services in the business,” added Heather N. Sugrue, VP sales and marketing.

The existing Recro Gainesville site is a GMP, DEA-licensed CDMO facility that encompasses an oral dosage formulation, process and analytical development space as well as GMP drug product manufacturing facilities for product development, clinical trial materials and commercial finished product.

To learn more about Recro’s CDMO capabilities, stop by Booth #1936 at AAPS or visit

About Recro Gainesville

Recro Gainesville provides solid dosage form development, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market. Specializing in extended release solid dose and DEA controlled substances, Recro has the experts to deliver clients’ most complex pharmaceutical development and manufacturing projects in its best-in-class, 120,000 square feet of manufacturing space. For more information about Recro’s flexible CDMO solutions, visit

About Recro Pharma

Recro Gainesville’s parent is Recro Pharma which is a specialty pharmaceutical company that operates through two business divisions, an Acute Care, hospital product division and a CDMO division, Recro Gainesville. The Acute Care division is primarily focused on developing innovative products for hospital and other acute care settings. The Acute Care division’s lead investigational product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor.
Print this page
Send to a friend
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>

White Papers

Another Successful Visit Against the Odds

Medical Research Network (MRN) Limited

Our dedicated team of nurses, couriers and project managers deliver, come rain or shine. Making sure a Clinical Trial visit can go ahead in the home can be a complex process, and last month bad weather nearly stopped play on an important Home Trial Support visit. Thanks to the commitment and dedication from the entire team it went ahead against the odds.
More info >>

Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement